[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatic-cell-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatic-cell-carcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100536472","value-of-68gaga-psma-11-petmri-in-the-assessment-of-liver-cirrhosis-100536472",false,"NCT06265272","Value of [68Ga]Ga-PSMA-11 PET\u002FMRI in the Assessment of Liver Cirrhosis","Technical Development and Clinical Validation of a Comprehensive One-stop Shop Assessment of the Cirrhotic Liver With [68Ga]Ga-PSMA-11 PET\u002FMRI","Inclusion Criteria:\n\n* Liver cirrhosis as diagnosed by imaging and\u002For clinical data, including pathology\n\nExclusion Criteria:\n\n* Any contraindication to PET, as in attached screening form\n* Any contraindication to MRI, as in attached screening form\n* Any contraindication to gadolinium-based contrast agent, including allergy to gadolinium, as in attached screening forms.\n* Pregnancy\n* Breast feeding.\n* Cumulative radiation exposure for research studies during the prior 12 months, combined with the exposure from this study, \\> 50 mSv\n* Inability to fit in the scanner: weight \\> 300 lbs or BMI \\> 33","ALL","18 Years","99 Years",{"count":20,"type":21},45,"ESTIMATED","OBSERVATIONAL","A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET\u002FMRI acquisition protocols.\n\nThe specific hypotheses include:\n\n* Ga-PSMA PET\u002FMRI may allow robust and reproducible noninvasive in vivo quantitation of hepatic macro and microhemodynamics in cirrhotic patients\n* Dedicated simultaneously acquired DWI sequences might quantitate liver fibrosis and improve hemodynamic quantitation.\n* Ga-PSMA PET\u002FMRI may allow noninvasive and reproducible quantitation of portal venous hypertension and predict its evolution, as well as response to treatments\n* Ga-PSMA PET\u002FMRI may improve noninvasive and reproducible qualitative and quantitative assessment of liver function, structure, nodules and predict evolution of cirrhosis",[25,26,27],"Liver Cirrhosis","Hepatic Cell Carcinoma","Portal Hypertension",[29,30,31,32,33],"PET\u002FMR","Cirrhosis","HCC","PSMA","68Ga PSMA","RECRUITING","2026-10-08",{"date":37,"type":38},"2026-10-14","ACTUAL",{"date":40,"type":38},"2023-12-10",{"date":42,"type":21},"2028-12-19",{"name":44,"class":45},"Massachusetts General Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100555686","phase-1-hryz-t102-tcr-t-cell-for-afp-positive-advanced-hcc-and-other-solid-tumors-100555686","NCT06515314","HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors","A Phase 1, Single-arm, Open-label, Dose-escalation Study of AFP Specific T Cell Receptor Transduced T Cells Injection（HRYZ-T102）in Patients With AFP Positive Advanced Hepatocellular Carcinoma and Other Solid Tumors","Inclusion Criteria:\n\n1. The patient must be willing to sign the informed consent form.\n2. Age ≥18 years and ≤75 years.\n3. HLA-A 02:03 allele positive\n4. Histologically-confirmed AFP positive hepatocellular carcinoma (HCC) or other solid tumor, No benefits from curative surgery or other local therapies are expected ,at least one prior line of systematic treatment at screening, judged by investigators.\n5. Fresh samples or formalin-fixed paraffin-embedded (FFPE) samples, immunohistochemistry (IHC)-stained AFP positive or serum AFP ≥400ng\u002Fml.\n6. Barcelona Clinic Liver Cancer (BCLC) stage C or B and Child-Pugh ≤7\n7. ECOG performance status ≤1.\n8. Estimated life expectancy ≥4 months.\n9. Patients must have at least one measurable lesion defined by RECIST 1.1.\n10. Patients with any organ dysfunction as defined below:\n\n    Leukocytes≥3.0 x 10\\^9\u002FL; blood platelets ≥75 x 10\\^9\u002FL; hemoglobin≥85g\u002FL; Absolute lymphocyte count≥0.8 x 10\\^9\u002FL Serum albumin ≥ 30g\u002FL; total bilirubin≤3×ULN; ALT\u002FAST≤3×ULN ; Creatinine clearance ≥50mL\u002Fmin; or serum creatinine ≤1.5×ULN; INR≤1.5×ULN; APTT≤1.5×ULN; LVEF≥50%; SpO2≥92%.\n11. Subjects with potential fertility must agree to use effective contraceptive methods during the whole trials period and at least 1 year after receiving HRYZ-T102 cell transfusion treatment. HCG test for female with potential fertility must be negative within 7 days before apheresis.\n\nExclusion Criteria:\n\n1. Toxicity of previous treatment has not been mitigated or ≤ Grade 1 at screening.\n2. Another primary malignancy within 5 years (with some exceptions for completely-resected early-stage tumors)\n3. With severe cardiovascular disease or presence of clinically-relevant central nervous system (CNS) disorders in six months before screening.\n4. Systematic autoimmune disorders requiring long-term systematic immunosuppression\n5. Have a history of hypersensitivity to cyclophosphamide or fludarabine, and it is known that any ingredient used in the treatment of this study will produce allergic reactions.\n6. Current presence of or previously with hepatic encephalopathy\n7. Organ transplanters and allogeneic cell transplanters.\n8. Have a history of gastrointestinal bleeding or a definite tendency to gastrointestinal bleeding within 3 months before screening\n9. Hereditary or acquired bleeding (e.g. coagulation dysfunction) or a tendency to clot\n10. Subject has active infection or unexplained fever during screening and prior to cell transfusion\n11. Have central nervous system metastasis with symptoms\n12. Known HIV or syphilis infection, and\u002For active hepatitis C virus infection.\n13. HBV infect subjects with HBV-DNA≥2000IU\u002Fml\n14. Pregnant or lactating female, or those whose HCG test is positive before enrollment.\n15. Known uncontrolled diabetes, pulmonary fibrosis, interstitial lung disease, acute lung disease or liver failure","75 Years",{"count":56,"type":21},12,"INTERVENTIONAL",[59],"PHASE1","This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to prior systematic treatments.",[26],"2025-11-24",{"date":64,"type":38},"2025-12-02",{"date":66,"type":38},"2024-10-17",{"date":68,"type":21},"2027-08-10",{"name":70,"class":71},"Shanghai Ruiliyuan Biotechnology Co., Ltd.","INDUSTRY"]